Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Nicorandil + atenolol is a **combination drug** composed of nicorandil, a potassium channel opener and nitrate vasodilator, and atenolol, a cardioselective beta-1 adrenergic receptor antagonist. This combination is utilized in the management of **chronic stable angina pectoris**. Nicorandil works by causing vasodilation of coronary arteries and peripheral vessels, reducing both preload and afterload, and opening ATP-sensitive potassium channels (KATP channels) in vascular smooth muscle. Atenolol reduces heart rate, contractility, and myocardial oxygen demand by antagonizing beta-1 adrenergic receptors, primarily affecting cardiac tissue. The additive effect may lead to enhanced anti-anginal efficacy through complementary mechanisms: nicorandil improves coronary blood flow and hemodynamics, while atenolol mitigates sympathetic cardiac stimulation and oxygen demand.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on nicorandil + atenolol.